MMP-Targeted Imaging Agents with Hydrophilic Groups
Solution Overview
Problem
Current MMP imaging agents exhibit poor target specificity, prolonged blood circulation time, and poor aqueous solubility, limiting their utility in clinical applications for diagnosing and treating MMP-related diseases such as abdominal aortic aneurysm.
Innovation Solution
Development of compounds that selectively bind to MMPs, labeled with radioisotopes like 99mTc, 18F, 111In, or 64Cu, which are designed to improve solubility and excretion rates, enabling effective imaging and potential therapeutic intervention.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If currently available MMP imaging agents are used, then MMP imaging can be performed, but target specificity is poor
Solution Approach 1:
The patent applies local quality by designing imaging agents with specific molecular structures that selectively bind to MMP enzymes at their active sites. The agents incorporate functional groups (such as hydroxamate, thiol, or carboxylate moieties) that specifically interact with the zinc ion in the MMP active site, ensuring localized and specific binding to the target enzyme while minimizing non-specific interactions with other proteins or tissues.
Solution Approach 2:
The patent employs parameter changes by systematically varying key molecular parameters of the imaging agents, including molecular weight, hydrophobicity, charge distribution, and functional group composition. These parameter optimizations are designed to enhance MMP binding affinity and specificity while improving pharmacokinetic properties such as blood clearance rate and renal excretion, thereby resolving the contradiction between imaging quality and target specificity.
2Duration of action of moving object
If currently available MMP imaging agents are used, then imaging can be performed, but blood circulation time is prolonged
Solution Approach 1:
The patent applies parameter changes by optimizing the molecular weight and hydrophilicity parameters of the imaging agents. The agents are designed with molecular weights typically between 200-1000 Da and incorporated hydrophilic groups (such as carboxylate, hydroxyl, or charged moieties) that enhance renal filtration. These parameter adjustments reduce plasma protein binding and increase glomerular filtration rate, thereby accelerating blood clearance while maintaining sufficient circulation time for effective imaging.
3Quantity of substance
If currently available MMP imaging agents are used, then imaging can be performed, but aqueous solubility is poor
Solution Approach 1:
The patent applies local quality by incorporating hydrophilic functional groups (such as carboxylate, hydroxyl, amine, or charged moieties) at specific locations on the molecular structure of the imaging agents. These local hydrophilic regions enhance overall aqueous solubility without compromising the hydrophobic interactions necessary for MMP binding, thereby improving solubility while maintaining binding efficacy and simplifying formulation requirements.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The compounds demonstrate strong and selective binding to MMPs, offering improved imaging specificity and faster clearance, facilitating early detection and treatment of MMP-related diseases like abdominal aortic aneurysm.
Implementation Method 1
The compounds demonstrate strong and selective binding to MMPs
Implementation Method 2
labeled with radioisotopes like 99mTc, 18F, 111In, or 64Cu
Data Source
AI summary
The present invention provides certain compounds, or salts or solvates thereof, which can be used as matrix metalloproteinase-targeted inhibitors or imaging agents.